BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35379046)

  • 1. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
    Ohigashi T; Maruo K; Sozu T; Gosho M
    Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified power prior with multiple historical trials for binary endpoints.
    Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
    Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary Endpoints.
    Isogawa N; Takeda K; Maruo K; Daimon T
    Ther Innov Regul Sci; 2020 May; 54(3):559-570. PubMed ID: 33301135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A scaled kernel density estimation prior for dynamic borrowing of historical information with application to clinical trial design.
    Warren JL; Wang Q; Ciarleglio MM
    Stat Med; 2024 Apr; 43(8):1615-1626. PubMed ID: 38345148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elastic priors to dynamically borrow information from historical data in clinical trials.
    Jiang L; Nie L; Yuan Y
    Biometrics; 2023 Mar; 79(1):49-60. PubMed ID: 34437714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
    Sawamoto R; Oba K; Matsuyama Y
    Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Power priors based on multiple historical studies for binary outcomes.
    Gravestock I; Held L
    Biom J; 2019 Sep; 61(5):1201-1218. PubMed ID: 30325059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The scale transformed power prior for use with historical data from a different outcome model.
    Alt EM; Nifong B; Chen X; Psioda MA; Ibrahim JG
    Stat Med; 2023 Jan; 42(1):1-14. PubMed ID: 36318875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating historical control information in ANCOVA models using the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2022 Nov; 13(6):681-696. PubMed ID: 35439840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.
    Bennett M; White S; Best N; Mander A
    Pharm Stat; 2021 May; 20(3):462-484. PubMed ID: 33474798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
    Wang X; Suttner L; Jemielita T; Li X
    J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian clinical trial design using historical data that inform the treatment effect.
    Psioda MA; Ibrahim JG
    Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.